Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

Overview of attention for article published in Cancer Chemotherapy and Pharmacology, January 2014

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (72nd percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,015 followers.

Phase I: AZD7762, a checkpoint kinase inhibitor, with gemcitabinem, advanced solid tumors. US. http://t.co/LeP3rwJORn

New Chk1 kinase inhibitor shows efficacy in #LungCancer but use limited by cardiac toxicity http://t.co/afojuQ0ert #lcsm

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.